EE200200497A - Peroraalselt manustatavad toimeainet reguleeritult vabastavad süsteemid tsiprofloksatsiini manustamiseks üks kord päevas - Google Patents

Peroraalselt manustatavad toimeainet reguleeritult vabastavad süsteemid tsiprofloksatsiini manustamiseks üks kord päevas

Info

Publication number
EE200200497A
EE200200497A EEP200200497A EEP200200497A EE200200497A EE 200200497 A EE200200497 A EE 200200497A EE P200200497 A EEP200200497 A EE P200200497A EE P200200497 A EEP200200497 A EE P200200497A EE 200200497 A EE200200497 A EE 200200497A
Authority
EE
Estonia
Prior art keywords
ciprofloxacin
daily administration
release systems
oral controlled
oral
Prior art date
Application number
EEP200200497A
Other languages
English (en)
Inventor
Talwar Naresh
N. Staniforth John
Rampal Ashok
Mukherji Gour
N. Vishwanathan Badri
Khera Brij
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of EE200200497A publication Critical patent/EE200200497A/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200200497A 2000-03-03 2001-02-28 Peroraalselt manustatavad toimeainet reguleeritult vabastavad süsteemid tsiprofloksatsiini manustamiseks üks kord päevas EE200200497A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51788700A 2000-03-03 2000-03-03
PCT/IB2001/000279 WO2001064183A1 (en) 2000-03-03 2001-02-28 Orally administered controlled delivery system for once daily administration of ciprofloxacin

Publications (1)

Publication Number Publication Date
EE200200497A true EE200200497A (et) 2004-02-16

Family

ID=24061635

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200497A EE200200497A (et) 2000-03-03 2001-02-28 Peroraalselt manustatavad toimeainet reguleeritult vabastavad süsteemid tsiprofloksatsiini manustamiseks üks kord päevas

Country Status (31)

Country Link
EP (1) EP1263409A1 (et)
JP (1) JP2003525229A (et)
KR (1) KR20030009374A (et)
CN (1) CN1420763A (et)
AP (2) AP2001002084A0 (et)
AR (1) AR032614A1 (et)
AU (1) AU3589701A (et)
BG (1) BG107055A (et)
BR (1) BR0108958A (et)
CA (1) CA2400950A1 (et)
CZ (1) CZ20022883A3 (et)
DO (1) DOP2001000130A (et)
EA (1) EA200200914A1 (et)
EC (1) ECSP013952A (et)
EE (1) EE200200497A (et)
GT (1) GT200100033A (et)
HN (1) HN2001000038A (et)
HR (1) HRP20020715A2 (et)
HU (1) HUP0204417A3 (et)
IL (1) IL151553A0 (et)
IS (1) IS6532A (et)
MX (1) MXPA02008568A (et)
NO (1) NO20024108L (et)
NZ (1) NZ520927A (et)
OA (1) OA12381A (et)
PE (1) PE20011113A1 (et)
PL (1) PL365071A1 (et)
SK (1) SK12542002A3 (et)
WO (1) WO2001064183A1 (et)
YU (1) YU66202A (et)
ZA (1) ZA200206764B (et)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20030229101A1 (en) * 2002-06-06 2003-12-11 Sherman Bernard Charles Tablets comprising ciprofloxacin hydrochloride
DE10351448A1 (de) 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
DE602005007205D1 (de) * 2005-07-19 2008-07-10 Ethypharm Sa Gastroretentive Zusammensetzungen und Verfahren zur Herstellung
DE602006012962D1 (de) * 2006-07-19 2010-04-29 Tabuk Pharmaceutical Mfg Co Pharmazeutische Zubereitungen von Ciprofloxacin
EP3247384B1 (en) 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate In vitro method of diagnosis of type 1 diabetes with insulin mimotopes
WO2017143438A1 (en) * 2016-02-23 2017-08-31 Matripharm International Inc. Dual-rate release formulation with high drug loading
EP3432877B1 (en) 2016-03-24 2023-01-11 ImmunoMolecular Therapeutics, Inc. D-alpha-methyldopa for treating autoimmune disease
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN109806237A (zh) * 2019-03-13 2019-05-28 悦康药业集团上海制药有限公司 一种乳酸环丙沙星泡腾片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
DE19839057A1 (de) * 1998-08-28 2000-03-02 Koch Berthold Spülluft-Regler für eine Trockenvorrichtung für Druckluft
SK285478B6 (sk) * 1998-09-14 2007-02-01 Ranbaxy Laboratories Limited Jednodenná formulácia na orálne podanie na kontrolované uvoľňovanie ciprofloxacínu

Also Published As

Publication number Publication date
NZ520927A (en) 2003-06-30
NO20024108D0 (no) 2002-08-28
AP1485A (en) 2005-10-31
PL365071A1 (en) 2004-12-27
BG107055A (bg) 2003-06-30
AU3589701A (en) 2001-09-12
PE20011113A1 (es) 2001-10-14
KR20030009374A (ko) 2003-01-29
WO2001064183A1 (en) 2001-09-07
HUP0204417A3 (en) 2005-03-29
HRP20020715A2 (en) 2004-12-31
AR032614A1 (es) 2003-11-19
NO20024108L (no) 2002-10-25
ECSP013952A (es) 2002-04-23
SK12542002A3 (sk) 2003-05-02
AP2001002084A0 (en) 2001-03-31
CZ20022883A3 (cs) 2003-04-16
OA12381A (en) 2004-09-06
HN2001000038A (es) 2005-03-23
CA2400950A1 (en) 2001-09-07
AP2002002627A0 (en) 2002-09-30
YU66202A (sh) 2005-09-19
CN1420763A (zh) 2003-05-28
IL151553A0 (en) 2003-04-10
GT200100033A (es) 2001-10-25
HUP0204417A2 (en) 2003-05-28
MXPA02008568A (es) 2003-02-24
ZA200206764B (en) 2003-03-04
JP2003525229A (ja) 2003-08-26
EP1263409A1 (en) 2002-12-11
IS6532A (is) 2002-08-28
EA200200914A1 (ru) 2003-02-27
DOP2001000130A (es) 2004-03-31
BR0108958A (pt) 2003-09-30

Similar Documents

Publication Publication Date Title
NO20020976L (no) Retarderte, orale, farmasöytiske administreringsformer
DE60138706D1 (de) Missbrauchssichere orale opioid-agonist zubereitungen
EE05581B1 (et) Aripiprasooli ravimlahus peroraalseks manustamiseks
NO20014035D0 (no) System for oral administrasjon av medikament
DE122008000001I1 (de) Orale Dosiszusammensetzungen mit verlängerter Freigabe
NO20030627L (no) Hydrogel-drevet medikament doseringsform
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
DK1335678T3 (da) Oralt behandlingssystem
ATE306253T1 (de) Orale bioadhäsive tablette mit verlängerter wirkstoffabgabe
DE50212546D1 (de) Orale darreichungsformen für propiverin oder seinen pharmazeutisch annehmbaren salzen mit verlängerter wirkstofffreisetzung
DK1043976T3 (da) Oral farmaceutisk doseringsform med langvarig frigivelse
NO20071303L (no) Farmasoytiske preparater
TR200003787A3 (tr) Kararli yavas salimli oral dozaj bilesimi.
DE60126089D1 (de) Verabreichungssystem
EE05375B1 (et) LevosimendaniÁfarmatseutilineÁlahus
NO20014738D0 (no) Tolperisonholdig farmasöytisk preparat for oral administrering
EE200200497A (et) Peroraalselt manustatavad toimeainet reguleeritult vabastavad süsteemid tsiprofloksatsiini manustamiseks üks kord päevas
AU2001284444A1 (en) Preparations for oral administration
FI20000780A (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
ATE348599T1 (de) Pharmazeutische dronedaron-zusammensetzung für die parenterale verabreichung
DK1216032T3 (da) Orale formuleringer med kontrolleret frigivelse
NO20040857L (no) Ny oral forlenget frigivelses doseringsform.
AU2001248943A1 (en) Pharmaceutical curative compound
NO20005877D0 (no) Munnhygiene-preparat for hemning av halitose
ITMI991742A0 (it) Bisplatino complessi attivi per via orale